Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Arvinas Inc

ARVN
Current price
33.45 USD -0.28 USD (-0.83%)
Last closed 33.44 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 2 470 765 056 USD
Yield for 12 month +22.71 %
1Y
3Y
5Y
10Y
15Y
ARVN
21.11.2021 - 28.11.2021

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut. Address: 5 Science Park, New Haven, CT, United States, 06511

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

71 USD

P/E ratio

Dividend Yield

Current Year

+78 500 000 USD

Last Year

+131 400 000 USD

Current Quarter

-43 100 000 USD

Last Quarter

+34 600 000 USD

Current Year

+71 800 000 USD

Last Year

+131 400 000 USD

Current Quarter

-44 800 000 USD

Last Quarter

+32 900 000 USD

Key Figures ARVN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -396 700 000 USD
Operating Margin TTM 383.53 %
PE Ratio
Return On Assets TTM -19.5 %
PEG Ratio
Return On Equity TTM -59.97 %
Wall Street Target Price 71 USD
Revenue TTM 78 500 000 USD
Book Value 9.71 USD
Revenue Per Share TTM 1.41 USD
Dividend Share
Quarterly Revenue Growth YOY 4.2 %
Dividend Yield
Gross Profit TTM 131 400 000 USD
Earnings Share -6.62 USD
Diluted Eps TTM -6.62 USD
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics ARVN

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ARVN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation ARVN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 17.6991
Enterprise Value Revenue 15.4605
Price Sales TTM 31.4747
Enterprise Value EBITDA -3.0741
Price Book MRQ 3.7446

Financials ARVN

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ARVN

For 52 weeks

13.57 USD 53.08 USD
50 Day MA 44.64 USD
Shares Short Prior Month 7 924 720
200 Day MA 30.7 USD
Short Ratio 10.9
Shares Short 8 600 168
Short Percent 14.09 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

411.84 USD Microsoft Corporation -5.76 (-1.38%)
Detailed analytics

ETF funds


M

MDAXEX

208.40 CHF iShares MDAX UCITS ETF (DE) -12.16 (-5.06%)
Detailed analytics

Metals


Gold

2205.6 USD Gold +35.66 (+1.64%)
Detailed analytics